11/7
08:36 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
11/1
01:04 pm
dnli
Rating for DNLI
Low
Report
Rating for DNLI
11/1
01:04 pm
dnli
Rating for DNLI
Low
Report
Rating for DNLI
10/11
10:03 am
dnli
Rating for DNLI
Medium
Report
Rating for DNLI
10/10
09:36 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "market perform" rating re-affirmed by analysts at Raymond James.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "market perform" rating re-affirmed by analysts at Raymond James.
10/10
09:36 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "market perform" rating re-affirmed by analysts at Raymond James.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "market perform" rating re-affirmed by analysts at Raymond James.
10/10
09:11 am
dnli
Rating for DNLI
Medium
Report
Rating for DNLI
10/10
09:11 am
dnli
Rating for DNLI
Medium
Report
Rating for DNLI
10/7
08:10 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating.
Medium
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating.
9/9
12:14 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $35.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $35.00 price target on the stock.
9/9
11:35 am
dnli
Rating for DNLI
Low
Report
Rating for DNLI
9/4
08:06 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.